-
1.发明公开公开(公告)号：US20240360162A1
公开(公告)日：2024-10-31
申请号：US18767494
申请日：2024-07-09
发明人： Derek John LONDESBROUGH , Christopher BROWN , Julian Scott NORTHEN , Gillian MOORE , Hemant Kashinath PATIL , David E. NICHOLS
CPC分类号： C07F9/5728 , A61K9/0053 , A61K9/2054 , A61K47/36 , A61K47/38 , C07D209/16 , C07B2200/13
摘要： This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
-
公开(公告)号：US20240350439A1
公开(公告)日：2024-10-24
申请号：US18759093
申请日：2024-06-28
发明人： Chong Hwan CHANG , Keun-Yeong JEONG
IPC分类号： A61K31/19 , A23L33/10 , A23L33/165 , A61K9/00 , A61K9/08 , A61K9/10 , A61K9/20 , A61K9/28 , A61K9/50 , A61K33/06 , A61K45/06 , A61K47/10 , A61K47/32 , A61K47/36 , A61K47/40 , A61K47/44 , A61P35/00
CPC分类号： A61K31/19 , A23L33/10 , A23L33/165 , A61K9/0019 , A61K9/0024 , A61K9/0053 , A61K9/0056 , A61K9/08 , A61K9/10 , A61K9/2054 , A61K9/2081 , A61K9/284 , A61K9/2846 , A61K9/2866 , A61K9/5026 , A61K9/5042 , A61K33/06 , A61K45/06 , A61K47/10 , A61K47/32 , A61K47/36 , A61K47/40 , A61K47/44 , A61P35/00 , A23V2002/00 , A23V2200/308 , A23V2250/042 , A23V2250/1578
摘要： The invention relates to pharmaceutical compositions comprising calcium lactate as an active agent and a polysaccharide, polymer, lipid, or a combination thereof. The pharmaceutical compositions are useful treating cancer. The invention also relates to foods and nutrient compositions comprising calcium lactate.
-
公开(公告)号：US20240342183A1
公开(公告)日：2024-10-17
申请号：US18752293
申请日：2024-06-24
发明人： Paul Sudhakar , Scott Boyer
IPC分类号： A61K31/53 , A61K9/00 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/36 , A61K47/38
CPC分类号： A61K31/53 , A61K9/0053 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/36 , A61K47/38
摘要： The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.
-
4.发明公开公开(公告)号：US20240335381A1
公开(公告)日：2024-10-10
申请号：US18629522
申请日：2024-04-08
发明人： Christopher W. Shade , Steven Tieu , James R Huey
IPC分类号： A61K9/107 , A61K9/00 , A61K31/57 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/24 , A61K47/36 , A61K47/44 , A61P5/24
CPC分类号： A61K9/1075 , A61K9/0014 , A61K31/57 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/24 , A61K47/36 , A61K47/44 , A61P5/24
摘要： Thickened microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described thickened microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the thickened MOIW microemulsion are modified with alcohol and an alcohol-lipid phase thickener and can solubilize alcohol-soluble species, including nonderivatized hormones. Preferably, the modified oil phase droplets of the thickened MOIW microemulsion directly solubilize nonderivatized hormones. The polar continuous “water” phase of the thickened MOIW microemulsion is modified with a continuous phase thickener. The modified oil phase droplets disperse into the modified polar continuous phase of the thickened MOIW microemulsion.
-
公开(公告)号：US20240335380A1
公开(公告)日：2024-10-10
申请号：US18533497
申请日：2023-12-08
发明人： Montserrat FOGUET , Lars MÖLLMANN
IPC分类号： A61K9/107 , A61K9/127 , A61K41/00 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/36
CPC分类号： A61K9/1075 , A61K9/127 , A61K41/0061 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/36
摘要： The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.
-
公开(公告)号：US20240325350A1
公开(公告)日：2024-10-03
申请号：US18619890
申请日：2024-03-28
发明人： Yogesh DANDIKER
IPC分类号： A61K31/365 , A61K9/70 , A61K31/455 , A61K47/10 , A61K47/36
CPC分类号： A61K31/365 , A61K9/7015 , A61K31/455 , A61K47/10 , A61K47/36
摘要： The present disclosure provides a sprayable liquid composition comprising about 1% w/v to about 20% w/v spironolactone or canrenone, about 30% w/v to about 97% w/v aliphatic solvent, about 1% w/v to about 10% w/v water, one or more film forming excipients, wherein the film forming excipient has a solubility in water at a pH between 1 and 10, and a penetration enhancer, wherein the composition forms a washable and/or a peelable film when sprayed on a skin surface, and wherein the spironolactone does not crystallize when the composition is applied to the skin surface. The disclosure also provides a method of treating acne, male and female pattern hair loss, hirsutism, hidradenitis suppurativa, polycystic ovary syndrome (PCOS), or combinations thereof in a subject in need thereof, the method comprising topically applying the composition described herein as a spray to a skin surface of the subject.
-
公开(公告)号：US20240316281A1
公开(公告)日：2024-09-26
申请号：US18554197
申请日：2022-03-31
申请人： Vitrean Inc.
CPC分类号： A61M5/31511 , A61K9/06 , A61K47/36 , A61M5/3286
摘要： A prefilled syringe containing a sterile ophthalmic pharmaceutical composition comprising an ultraconcentrated hydrogel and a pharmaceutically acceptable carrier, the prefilled syringe capable of storing the ultraconcentrated hydrogel and injecting the ultraconcentrated hydrogel with a reduced injection force into a biologic tissue.
-
公开(公告)号：US20240315995A1
公开(公告)日：2024-09-26
申请号：US18577696
申请日：2022-07-08
申请人： GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. , OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD.
发明人： Chiyong Liang , Yandong Wang , Chuiliang Yu , Liang Li , Yaping Xue , Meirong Wu
IPC分类号： A61K31/192 , A61K47/14 , A61K47/18 , A61K47/36 , A61P27/02
CPC分类号： A61K31/192 , A61K47/14 , A61K47/183 , A61K47/186 , A61K47/36 , A61P27/02
摘要： The present invention relates to an application of loxoprofen sodium or a composition containing loxoprofen sodium in the preparation of a drug for preventing and/or treating the dry eye disease.
-
公开(公告)号：US20240315966A1
公开(公告)日：2024-09-26
申请号：US18577690
申请日：2022-07-08
申请人： GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. , OCUSUN OPHTHALMIC PHARMACEUTICAL (GUANGZHOU) CO., LTD.
发明人： Shengan Zhou , Chuiliang Yu , Yandong Wang , Ximing Feng , Yaxiong Li , Meirong Wu
IPC分类号： A61K9/08 , A61K9/06 , A61K31/192 , A61K47/02 , A61K47/18 , A61K47/26 , A61K47/36 , A61P27/02
CPC分类号： A61K9/08 , A61K9/06 , A61K31/192 , A61K47/02 , A61K47/183 , A61K47/186 , A61K47/26 , A61K47/36 , A61P27/02
摘要： A composition containing loxoprofen sodium. The composition comprises loxoprofen sodium, sodium hyaluronate and polysorbate 80, wherein the molecular weight of sodium hyaluronate is 0.8×106−1.6×106. The composition has good stability and a long shelf life and is convenient to use.
-
公开(公告)号：US20240294918A1
公开(公告)日：2024-09-05
申请号：US17802916
申请日：2021-02-27
申请人： MICROCURES, INC.
IPC分类号： C12N15/113 , A61K9/107 , A61K9/70 , A61K47/06 , A61K47/10 , A61K47/20 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/42 , A61P17/02
CPC分类号： C12N15/1137 , A61K9/1075 , A61K9/7007 , A61K47/06 , A61K47/10 , A61K47/20 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/42 , A61P17/02 , C12N2310/14 , C12N2310/315 , C12N2310/321
摘要： Nucleic acid molecules and compositions thereof targeted to fidgetin-like 2, and methods of their use in treating a wound or scar in a human subject are described.
-
-
-
-
-
-
-
-
-
搜索结果
6678 条记录 (耗时 0.042 秒)
